BioPharmSignal logoBioPharmSignal

Biotech News

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Ocugen (OCGN)OcugenPartnership

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.

Related news

OCGNOcugen2026-09-25 11:02 EST

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

OCGNOcugen2026-09-01 11:02 EST

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

SNYSanofi2026-09-14 13:03 EST

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

SNYSanofi2026-10-01 05:00 EST

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

NTLAIntellia2026-09-08 12:00 EST

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

BLTEBelite Bio2026-10-14 20:00 EST

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1

IRIXIRIDEX2026-10-12 11:00 EST

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

RCKTRocket Pharmaceuticals2026-10-07 13:36 EST

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

TSHATaysha Gene Therapies2026-10-01 12:00 EST

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

View all latest news

Ocugen

Gene Therapies for Retinal Disease Ocugen develops one-time gene therapies for inherited and acquired causes of blindness. Its lead ophthalmology programs are designed to address broad patient populations rather than only individuals with a single disease-causing mutation. Modifier Gene Therapy Platform The platform delivers master...

Recent company news

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

OCGNOcugen2026-10-14 10:30 EST

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

OCGNOcugen2026-10-06 11:02 EST

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

OCGNOcugen2026-09-30 11:02 EST

Ocugen to Participate in Upcoming Scientific Conferences

OCGNOcugen2026-09-29 11:02 EST

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Stock data

Close
0.82 USD
Market cap
453.62M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States